Pfizer Pipeline Bet to Show If Drugmaker Has BlockbusterDrew Armstrong
Pfizer Inc.’s Chief Executive Officer Ian Read will find out in the next six months whether his plan to shed units and focus on new drugs will pay off, with three top products awaiting approval or key data.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Fewest Jobless Claims Since 1973 Show Firm U.S. Job Market
- Greenwich Mansion Listings Pulled to Wait for a Better Day
- U.S. Stocks Climb With Treasuries as Dollar Slides: Markets Wrap
- The U.K.'s $86 Billion Pension Problem Is About to Solve Itself
- Germans Are Going Wild for a Show Set During the Dawn of the Nazis